Moleculin Biotech, INC

Moleculin Biotech, Inc. announced the closing of a public offering, raising approximately $9.3 million to fund its clinical development programs.

Moleculin Biotech announces updated preliminary blinded results from its Phase 2/3 MIRACLE trial for Annamycin in R/R AML, showing promising remission rates, especially in patients who failed prior venetoclax therapy.

Moleculin Biotech announced positive preliminary efficacy results from its Phase 2/3 MIRACLE trial, showing Annamycin treatment arms significantly outperformed the control in patients with relapsed or refractory acute myeloid leukemia.

Moleculin Biotech provides an investor presentation and reports on warrant exercises generating $2.7 million in gross proceeds.

Independent market research indicates strong physician and payer interest in Annamycin for treating relapsed/refractory AML.

Moleculin Biotech presented new clinical data at ASCO 2026 demonstrating no detectable cardiotoxicity for its lead drug candidate, Annamycin.

Moleculin Biotech reports significant net losses and negative stockholders' equity, raising substantial doubt about its ability to continue as a going concern, while advancing its lead drug Annamycin in Phase 3 trials.

Moleculin Biotech reported a widened net loss in Q2 2025, facing Nasdaq delisting concerns, while advancing its lead drug Annamycin into a pivotal Phase 3 trial with promising preclinical data and patent grants.

Moleculin Biotech's Q1 2025 report details financial results and provides updates on the clinical development of Annamycin, including progress on the Phase 3 MIRACLE trial.

Moleculin Biotech's Q3 2024 report highlights progress in Annamycin clinical trials and financial updates, including a recent equity raise.

Moleculin Biotech's Q2 2024 results show a net loss, but the company is progressing Annamycin to a Phase 3 trial for AML treatment.

Moleculin Biotech's Q1 2024 report shows a net loss but highlights positive clinical trial data for Annamycin and new patent issuances.

Moleculin Biotech, Inc. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, primarily to include previously omitted Part III information regarding directors, executive compensation, and corporate governance.

Moleculin Biotech files an amendment to its 2024 annual report to include certain interactive data file tagging and restate items 10 through 14.

Moleculin Biotech files an amendment to its annual report to include information about directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accountant fees.

Moleculin Biotech's 10-K filing highlights progress in Annamycin's clinical development, particularly the Phase 3 MIRACLE trial for relapsed/refractory AML, while navigating financial constraints and regulatory landscapes.

Moleculin Biotech has filed an amendment to its annual report to include information about directors, executive compensation, and corporate governance, which was previously omitted.

Moleculin Biotech's 10-K filing highlights ongoing clinical trials for Annamycin and other drug candidates, along with financial results for 2023.

Donald H. Picker, Chief Science Officer of Moleculin Biotech, Inc., reported transactions involving restricted stock units and common stock.

Walter V. Klemp, CEO and President of Moleculin Biotech, Inc., reported transactions involving restricted stock units and common stock.

Moleculin Biotech's Chief Financial Officer, Jonathan P. Foster, has acquired company shares through restricted stock units and exercised warrants, indicating continued investment in the company.

Moleculin Biotech's Chief Scientific Officer, Donald H. Picker, was granted 400,000 derivative securities, including stock options and performance-based restricted stock units.

Moleculin Biotech's EVP & CFO, Jonathan P. Foster, was granted 600,000 stock options and 400,000 performance-based restricted stock units.

Moleculin Biotech's CEO and President, Walter V. Klemp, was granted 830,000 stock options and 750,000 performance-based restricted stock units.

Moleculin Biotech, Inc. calls a Special Meeting to approve the issuance of up to 2.61 million shares from warrant exercises and a corporate name change to Moleculin Inc.

Moleculin Biotech, Inc. calls a Special Meeting to approve the issuance of up to 64.86 million shares from warrant exercises and a corporate name change to Moleculin Inc.

Moleculin Biotech, Inc. has filed definitive additional proxy materials with the U.S. Securities and Exchange Commission.

Moleculin Biotech, Inc. is seeking shareholder approval for a significant increase in authorized common stock, a potential reverse stock split, and the issuance of shares related to recent warrant exercises, alongside executive compensation and board elections at its upcoming Annual Meeting.

Moleculin Biotech is seeking stockholder approval to issue shares upon the exercise of warrants issued in a private placement to comply with Nasdaq Listing Rule 5635(d).

Moleculin Biotech, Inc. has filed a definitive proxy statement with the SEC.

Moleculin Biotech announces a public offering of up to 4,566,210 shares of common stock and accompanying warrants, aiming to raise approximately $9.1 million for clinical development.

Moleculin Biotech, Inc. has filed a Form S-1 registration statement to offer shares of common stock, pre-funded warrants, and common warrants to the public.

Moleculin Biotech, Inc. is seeking to raise up to $6.8 million through a 'reasonable best efforts' public offering of common stock and warrants, as the company faces Nasdaq non-compliance and a critical need for near-term capital to fund its drug development programs.

Moleculin Biotech, Inc. is conducting a 'reasonable best efforts' public offering of common stock and Series E warrants to fund its clinical development, particularly its lead drug Annamycin for AML, while simultaneously facing a Nasdaq non-compliance notice regarding its stockholders' equity.

Moleculin Biotech, Inc. has initiated a 'reasonable best efforts' public offering of common stock and warrants to raise up to $7.5 million, while simultaneously addressing a Nasdaq non-compliance notice regarding its stockholders' equity.

Moleculin Biotech, Inc. has initiated a 'reasonable best efforts' public offering of up to $10 million in common stock and warrants to fund clinical development, while simultaneously addressing a Nasdaq non-compliance notice regarding its minimum stockholders' equity.

Armistice Capital and Steven Boyd updated their beneficial ownership in Moleculin Biotech, Inc., reporting a 4.99% stake.

Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 8.93% in Moleculin Biotech, Inc., holding 1,250,000 shares of common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Moleculin Biotech, Inc. as of December 31, 2024.